VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma
Table 4
Quantitative analysis of allelic and genotypic frequencies of VEGF-C936T and VEGF-A1154G polymorphisms in patients with hepatocellular carcinoma (G1), cirrhosis (G2), and controls (G3), considering serum levels of VEGF.
(a) VEGF-C936T
VEGF serum levels × polymorphisms
Intergroups value G1 × G2 × G3
G1 ()
G2 ()
G3 ()
Median (pg/mL) (Minimum–maximum)
C/C
250.5 () (101.9–1120.2)
191.7 () (7.23–992.95)
185.7 () (41.4–666.1)
0.0700
_ /T
430.0 ()▲■ (133.35–1795.1)
173.5 ()▲ (50.1–556.2)
113.9 ()■ (31.56–225.45)
0.0038
Intragroup value
0.0285
0.2868
0.0955
(b) VEGF-A1154G
VEGF serum levels × polymorphisms
Intergroups value G1 × G2 × G3
G1 ()
G2 ()
G3 ()
Median (pg/mL) (Minimum–maximum)
G/G
238.2 () (101.9–1795.1)
182.8 () (50.1–992.95)
182.2 () (31.56–666.1)
0.0644
_ /A
297.75 ()● (104.25–1256.3)
183.3 ()● (7.23–556.17)
185.2 () (41.4–534.0)
0.0069
Intragroup value
0.18
0.1602
0.0284
Mann-Whitney and Kruskal-Wallis tests for intragroup and intergroup analyses, respectively; VEGF = vascular endothelial growth factor; = number of subjects; ▲ and ■: ; ●: .
